Last 12 months
Inside the activity.
6 purchase rows · 12 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 4 |
| Mar 2026 | 1 | 0 |
| Apr 2026 | 1 | 0 |
| May 2026 | 1 | 0 |
| Jun 2026 | 1 | 4 |
| Jul 2026 | 1 | 0 |
| Aug 2026 | 1 | 4 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 11, 2022 Filed Mar 15, 2022 16:37 UTC |
Lachey JenniferChief Scientific Officer
|
SaleCommon Stock | 875 | $54.54 | $47,722.50 |
DisclosureSEC source: 0001209191-22-018836 · doc4.xml · nonDerivative · entry 4 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,700 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.225 to $55.13 inclusive. Read SEC document |
| March 11, 2022 Filed Mar 15, 2022 16:37 UTC |
Lachey JenniferChief Scientific Officer
|
SaleCommon Stock | 713 | $53.36 | $38,045.68 |
DisclosureSEC source: 0001209191-22-018836 · doc4.xml · nonDerivative · entry 3 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,575 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.06 to $53.83 inclusive. Read SEC document |
| March 11, 2022 Filed Mar 15, 2022 16:37 UTC |
Lachey JenniferChief Scientific Officer
|
SaleCommon Stock | 1,062 | $52.43 | $55,680.66 |
DisclosureSEC source: 0001209191-22-018836 · doc4.xml · nonDerivative · entry 2 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,288 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.03 to $53.025 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4). Read SEC document |
| March 11, 2022 Filed Mar 15, 2022 16:37 UTC |
Lachey JenniferChief Scientific Officer
|
Exercise / conversionCommon Stock | 2,650 | $0.30 | $795.00 |
DisclosureSEC source: 0001209191-22-018836 · doc4.xml · nonDerivative · entry 1 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,350 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 16:26 UTC |
Lachey JenniferChief Scientific Officer
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,650 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001209191-22-009792 · doc4.xml · derivative · entry 5 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,305 Underlying: Common Stock · 2,650 shares Expires 2028-03-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 16:26 UTC |
Lachey JenniferChief Scientific Officer
|
SaleCommon Stock | 199 | $53.10 | $10,566.90 |
DisclosureSEC source: 0001209191-22-009792 · doc4.xml · nonDerivative · entry 4 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,700 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.06 to $53.17 inclusive. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 16:26 UTC |
Lachey JenniferChief Scientific Officer
|
SaleCommon Stock | 1,378 | $52.35 | $72,138.30 |
DisclosureSEC source: 0001209191-22-009792 · doc4.xml · nonDerivative · entry 3 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,899 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.99 to $52.805 inclusive. Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 16:26 UTC |
Lachey JenniferChief Scientific Officer
|
SaleCommon Stock | 1,073 | $51.50 | $55,259.50 |
DisclosureSEC source: 0001209191-22-009792 · doc4.xml · nonDerivative · entry 2 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,277 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.97 to $51.63 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4). Read SEC document |
| February 11, 2022 Filed Feb 15, 2022 16:26 UTC |
Lachey JenniferChief Scientific Officer
|
Exercise / conversionCommon Stock | 2,650 | $0.30 | $795.00 |
DisclosureSEC source: 0001209191-22-009792 · doc4.xml · nonDerivative · entry 1 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,350 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 16:45 UTC |
Rovaldi ChristopherChief Operating Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $49.34 | $0.00 |
DisclosureSEC source: 0001209191-22-006830 · doc4.xml · derivative · entry 1 Rovaldi Christopher · CIK 0001706040 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-01-31 F1 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option shall vest on February 1, 2023, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| January 21, 2022 Filed Jan 25, 2022 16:12 UTC |
Cooper Simon PeterChief Medical Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $46.30 | $0.00 |
DisclosureSEC source: 0001209191-22-004758 · doc4.xml · derivative · entry 1 Cooper Simon Peter · CIK 0001877225 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-01-20 F1 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option shall vest on January 19, 2023, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| January 21, 2022 Filed Jan 25, 2022 16:14 UTC |
Lachey JenniferChief Scientific Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $46.30 | $0.00 |
DisclosureSEC source: 0001209191-22-004763 · doc4.xml · derivative · entry 1 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-01-20 F1 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option shall vest on January 19, 2023, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| January 21, 2022 Filed Jan 25, 2022 21:17 UTC |
Seehra JasbirDirector · Chief Executive Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 165,000 | $0.00 Strike: $46.30 | $0.00 |
DisclosureSEC source: 0001209191-22-004771 · doc4.xml · derivative · entry 1 Seehra Jasbir · CIK 0001732369 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,000 Underlying: Common Stock · 165,000 shares Expires 2032-01-20 F1 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option shall vest on January 19, 2023, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| January 21, 2022 Filed Jan 25, 2022 21:15 UTC |
Regnante KeithChief Financial Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $46.30 | $0.00 |
DisclosureSEC source: 0001209191-22-004767 · doc4.xml · derivative · entry 1 Regnante Keith · CIK 0001682068 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-01-20 F1 · derivative.exercise_date: One-fourth (1/4th) of the shares subject to the option shall vest on January 19, 2023, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date. Read SEC document |
| January 11, 2022 Filed Jan 13, 2022 16:39 UTC |
Lachey JenniferChief Scientific Officer
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,650 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001209191-22-003198 · doc4.xml · derivative · entry 5 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,955 Underlying: Common Stock · 2,650 shares Expires 2028-03-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| January 11, 2022 Filed Jan 13, 2022 16:39 UTC |
Lachey JenniferChief Scientific Officer
|
SaleCommon Stock | 1,134 | $54.45 | $61,746.30 |
DisclosureSEC source: 0001209191-22-003198 · doc4.xml · nonDerivative · entry 4 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,700 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.075 to $54.85 inclusive. Read SEC document |
| January 11, 2022 Filed Jan 13, 2022 16:39 UTC |
Lachey JenniferChief Scientific Officer
|
SaleCommon Stock | 1,196 | $53.56 | $64,057.76 |
DisclosureSEC source: 0001209191-22-003198 · doc4.xml · nonDerivative · entry 3 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,834 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.035 to $53.98 inclusive. Read SEC document |
| January 11, 2022 Filed Jan 13, 2022 16:39 UTC |
Lachey JenniferChief Scientific Officer
|
SaleCommon Stock | 320 | $52.01 | $16,643.20 |
DisclosureSEC source: 0001209191-22-003198 · doc4.xml · nonDerivative · entry 2 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,030 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.695 to $52.45 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4). Read SEC document |
| January 11, 2022 Filed Jan 13, 2022 16:39 UTC |
Lachey JenniferChief Scientific Officer
|
Exercise / conversionCommon Stock | 2,650 | $0.30 | $795.00 |
DisclosureSEC source: 0001209191-22-003198 · doc4.xml · nonDerivative · entry 1 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,350 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 05, 2022 Filed Jan 6, 2022 00:14 UTC |
Knowles JuliusDirector
|
SaleCommon Stock | 435 | $59.00 | $25,665.00 |
DisclosureSEC source: 0001209191-22-001990 · doc4.xml · nonDerivative · entry 24 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 232,727 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F15 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.76 to $59.25 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| January 05, 2022 Filed Jan 6, 2022 00:14 UTC |
Knowles JuliusDirector
|
SaleCommon Stock | 667 | $59.00 | $39,353.00 |
DisclosureSEC source: 0001209191-22-001990 · doc4.xml · nonDerivative · entry 23 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 341,574 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F15 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.76 to $59.25 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| January 05, 2022 Filed Jan 6, 2022 00:14 UTC |
Knowles JuliusDirector
|
SaleCommon Stock | 886 | $58.20 | $51,565.20 |
DisclosureSEC source: 0001209191-22-001990 · doc4.xml · nonDerivative · entry 22 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 233,162 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F14 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.63 to $58.62 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| January 05, 2022 Filed Jan 6, 2022 00:14 UTC |
Knowles JuliusDirector
|
SaleCommon Stock | 1,356 | $58.20 | $78,919.20 |
DisclosureSEC source: 0001209191-22-001990 · doc4.xml · nonDerivative · entry 21 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 342,241 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F14 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.63 to $58.62 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| January 05, 2022 Filed Jan 6, 2022 00:14 UTC |
Knowles JuliusDirector
|
SaleCommon Stock | 271 | $57.23 | $15,509.33 |
DisclosureSEC source: 0001209191-22-001990 · doc4.xml · nonDerivative · entry 20 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 234,048 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.63 to $57.56 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| January 05, 2022 Filed Jan 6, 2022 00:14 UTC |
Knowles JuliusDirector
|
SaleCommon Stock | 419 | $57.23 | $23,979.37 |
DisclosureSEC source: 0001209191-22-001990 · doc4.xml · nonDerivative · entry 19 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 343,597 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.63 to $57.56 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| January 05, 2022 Filed Jan 7, 2022 16:35 UTC |
Lachey JenniferChief Scientific Officer
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,650 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001209191-22-002416 · doc4.xml · derivative · entry 3 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,605 Underlying: Common Stock · 2,650 shares Expires 2028-03-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| January 05, 2022 Filed Jan 7, 2022 16:35 UTC |
Lachey JenniferChief Scientific Officer
|
SaleCommon Stock | 2,650 | $60.00 | $159,000.00 |
DisclosureSEC source: 0001209191-22-002416 · doc4.xml · nonDerivative · entry 2 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,700 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| January 05, 2022 Filed Jan 7, 2022 16:35 UTC |
Lachey JenniferChief Scientific Officer
|
Exercise / conversionCommon Stock | 2,650 | $0.30 | $795.00 |
DisclosureSEC source: 0001209191-22-002416 · doc4.xml · nonDerivative · entry 1 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,350 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 00:14 UTC |
Knowles JuliusDirector
|
SaleCommon Stock | 2,195 | $58.86 | $129,197.70 |
DisclosureSEC source: 0001209191-22-001990 · doc4.xml · nonDerivative · entry 18 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 234,319 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.57 to $59.36 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 00:14 UTC |
Knowles JuliusDirector
|
SaleCommon Stock | 3,367 | $58.86 | $198,181.62 |
DisclosureSEC source: 0001209191-22-001990 · doc4.xml · nonDerivative · entry 17 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 344,016 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.57 to $59.36 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 00:14 UTC |
Knowles JuliusDirector
|
SaleCommon Stock | 2,704 | $57.99 | $156,804.96 |
DisclosureSEC source: 0001209191-22-001990 · doc4.xml · nonDerivative · entry 16 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 236,514 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.56 to $58.55 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 00:14 UTC |
Knowles JuliusDirector
|
SaleCommon Stock | 4,151 | $57.99 | $240,716.49 |
DisclosureSEC source: 0001209191-22-001990 · doc4.xml · nonDerivative · entry 15 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 347,383 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.56 to $58.55 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 00:14 UTC |
Knowles JuliusDirector
|
SaleCommon Stock | 1,113 | $56.95 | $63,385.35 |
DisclosureSEC source: 0001209191-22-001990 · doc4.xml · nonDerivative · entry 14 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 239,218 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.56 to $57.53 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 00:14 UTC |
Knowles JuliusDirector
|
SaleCommon Stock | 1,707 | $56.95 | $97,213.65 |
DisclosureSEC source: 0001209191-22-001990 · doc4.xml · nonDerivative · entry 13 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 351,534 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.56 to $57.53 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 00:14 UTC |
Knowles JuliusDirector
|
SaleCommon Stock | 1,383 | $56.10 | $77,586.30 |
DisclosureSEC source: 0001209191-22-001990 · doc4.xml · nonDerivative · entry 12 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 240,331 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.555 to $56.53 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 00:14 UTC |
Knowles JuliusDirector
|
SaleCommon Stock | 2,124 | $56.10 | $119,156.40 |
DisclosureSEC source: 0001209191-22-001990 · doc4.xml · nonDerivative · entry 11 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 353,241 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.555 to $56.53 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 00:14 UTC |
Knowles JuliusDirector
|
SaleCommon Stock | 524 | $54.95 | $28,793.80 |
DisclosureSEC source: 0001209191-22-001990 · doc4.xml · nonDerivative · entry 10 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 241,714 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.50 to $55.48 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 00:14 UTC |
Knowles JuliusDirector
|
SaleCommon Stock | 794 | $54.95 | $43,630.30 |
DisclosureSEC source: 0001209191-22-001990 · doc4.xml · nonDerivative · entry 9 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 355,365 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.50 to $55.48 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 00:14 UTC |
Knowles JuliusDirector
|
SaleCommon Stock | 162 | $59.40 | $9,622.80 |
DisclosureSEC source: 0001209191-22-001990 · doc4.xml · nonDerivative · entry 8 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 242,238 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.36 to $59.45 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 00:14 UTC |
Knowles JuliusDirector
|
SaleCommon Stock | 249 | $59.40 | $14,790.60 |
DisclosureSEC source: 0001209191-22-001990 · doc4.xml · nonDerivative · entry 7 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 356,159 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.36 to $59.45 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 00:14 UTC |
Knowles JuliusDirector
|
SaleCommon Stock | 3,412 | $58.96 | $201,171.52 |
DisclosureSEC source: 0001209191-22-001990 · doc4.xml · nonDerivative · entry 6 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 242,400 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.35 to $59.33 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 00:14 UTC |
Knowles JuliusDirector
|
SaleCommon Stock | 5,236 | $58.96 | $308,714.56 |
DisclosureSEC source: 0001209191-22-001990 · doc4.xml · nonDerivative · entry 5 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 356,408 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.35 to $59.33 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 00:14 UTC |
Knowles JuliusDirector
|
SaleCommon Stock | 3,318 | $57.83 | $191,879.94 |
DisclosureSEC source: 0001209191-22-001990 · doc4.xml · nonDerivative · entry 4 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 245,812 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.30 to $58.24 inclusive. F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 00:14 UTC |
Knowles JuliusDirector
|
SaleCommon Stock | 5,094 | $57.83 | $294,586.02 |
DisclosureSEC source: 0001209191-22-001990 · doc4.xml · nonDerivative · entry 3 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 361,644 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.30 to $58.24 inclusive. F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 00:14 UTC |
Knowles JuliusDirector
|
SaleCommon Stock | 2,406 | $56.82 | $136,708.92 |
DisclosureSEC source: 0001209191-22-001990 · doc4.xml · nonDerivative · entry 2 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 249,130 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.30 to $57.29 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7), (8), (9), (10), (11), (12), (13), (14) and (15). F4 · ownership.nature: The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II. Read SEC document |
| January 03, 2022 Filed Jan 6, 2022 00:14 UTC |
Knowles JuliusDirector
|
SaleCommon Stock | 3,678 | $56.82 | $208,983.96 |
DisclosureSEC source: 0001209191-22-001990 · doc4.xml · nonDerivative · entry 1 Knowles Julius · CIK 0001808365 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 366,738 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.30 to $57.29 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6), (7), (8), (9), (10), (11), (12), (13), (14) and (15). F3 · ownership.nature: The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I. Read SEC document |
| December 15, 2021 Filed Dec 15, 2021 16:48 UTC |
Lachey JenniferChief Scientific Officer
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 735 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001209191-21-069767 · doc4.xml · derivative · entry 8 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,255 Underlying: Common Stock · 735 shares Expires 2028-03-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| December 15, 2021 Filed Dec 15, 2021 16:48 UTC |
Lachey JenniferChief Scientific Officer
|
SaleCommon Stock | 735 | $50.00 | $36,750.00 |
DisclosureSEC source: 0001209191-21-069767 · doc4.xml · nonDerivative · entry 6 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,700 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| December 15, 2021 Filed Dec 15, 2021 16:48 UTC |
Lachey JenniferChief Scientific Officer
|
Exercise / conversionCommon Stock | 735 | $0.30 | $220.50 |
DisclosureSEC source: 0001209191-21-069767 · doc4.xml · nonDerivative · entry 5 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,435 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 16:48 UTC |
Lachey JenniferChief Scientific Officer
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,915 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001209191-21-069767 · doc4.xml · derivative · entry 7 Lachey Jennifer · CIK 0001808322 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,990 Underlying: Common Stock · 1,915 shares Expires 2028-03-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Immediately exercisable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.